SCHEMBL4941482

SCHEMBL4941482

Fc1cc(CCCC2CCN(Cc3nc4cccc5c4n3CCO5)CC2)cc(C(F)(F)F)c1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LIPG Q9Y5X9 2/20 0.36
DRD4 P21917 4/20 0.36
DRD2 P14416 3/20 0.36
GRM2 Q14416 3/20 0.36
ALDH1A2 O94788 1/20 0.35
ALDH1A1 P00352 1/20 0.35
ALDH2 P05091 1/20 0.35
ALDH3A1 P30838 1/20 0.35
ALDH1A3 P47895 1/20 0.35
MAOB P27338 1/20 0.35
HTT P42858 1/20 0.34
ACHE P22303 1/20 0.33
CXCR3 P49682 1/20 0.33
SIGMAR1 Q99720 1/20 0.33
CHRM2 P08172 1/20 0.33
CHRM1 P11229 1/20 0.33
DRD3 P35462 1/20 0.33
CCR5 P51681 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4947552 0.87 CYP2D6 (0.39) LIPGDRD4MAOBACHE
SCHEMBL4745230 0.82 MAOB (0.43) LIPGDRD4MAOB
SCHEMBL4163880 0.81 GRM2 (0.45) DRD4DRD2GRM2ALDH1A2ALDH1A1
SCHEMBL13993062 0.79 GRM2 (0.57) DRD4DRD2GRM2HTTCHRM2
SCHEMBL4945433 0.79 DRD2 (0.36) LIPGDRD4DRD2
SCHEMBL4157977 0.78 GRM2 (0.61) DRD4DRD2GRM2DRD3
SCHEMBL4749464 0.76 SLC6A3 (0.36) DRD4DRD2MAOBACHEDRD3
SCHEMBL4751305 0.76 SLC6A3 (0.38) LIPG
SCHEMBL13993059 0.76 DRD2 (0.43) DRD4DRD2GRM2DRD3
SCHEMBL14611321 0.76 CYP2D6 (0.35) MAOBACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080318999-A1 Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators ASTRAZENECA AB (SE) 2008-12-25 US claimed
US-20070032469-A1 Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators ASTRAZENECA AB (SE) 2007-02-08 US claimed
US-20080318999-A1 Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators ASTRAZENECA AB (SE) 2008-12-25 US disclosed
US-20080318999-A1 Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators ASTRAZENECA AB (SE) 2008-12-25 US disclosed
WO-2007018998-A2 TRICYCLIC BENZIMIDAZOLES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2007-02-15 WO disclosed
US-20070032469-A1 Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators ASTRAZENECA AB (SE) 2007-02-08 US disclosed
US-20070032469-A1 Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators ASTRAZENECA AB (SE) 2007-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032469-A1 Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators GRM2, GRM1, GRIN2B LIPG 4882/4885DRD4 129/4885DRD2 51/4885
US-20080318999-A1 Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators GRM2, GRM1, GRIN2B LIPG 4882/4885DRD4 129/4885DRD2 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.